Denali Therapeutics (DNLI) announced that its partner Sanofi (SNY) has commenced dosing in a Phase 2 study of SAR443820 in individuals with multiple sclerosis. SAR443820 is a central nervous system-penetrant investigational small molecule inhibitor of RIPK1. Under the collaboration agreement, Denali will receive a milestone payment of $25 million from Sanofi for initiation of the Phase 2 study with SAR443820 in multiple sclerosis. Denali is entitled to receive additional development and regulatory milestone payments. Denali will share profits and losses equally with Sanofi for CNS-penetrant products sold in the United States and China, and Denali is entitled to receive royalties on net sales for CNS-penetrant products sold outside of the United States and China.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DNLI:
- Centogene, Denali extend observational study on Parkinson’s disease genetics
- Denali Therapeutics announces 2023 milestones
- Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
- Denali interim P1b study results in ALS ‘positive,’ says Cantor Fitzgerald
- Denali Therapeutics initiated with an Outperform at Cowen